Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 03

218P - Prognostic role of apoptotic index in acute lymphoblastic leukemia

Date

03 Dec 2022

Session

Poster viewing 03

Topics

Clinical Research;  Cancer Biology

Tumour Site

Leukaemias

Presenters

Ramya Ramesh

Citation

Annals of Oncology (2022) 33 (suppl_9): S1515-S1520. 10.1016/annonc/annonc1127

Authors

R. Ramesh1, S. Kayal1, P. MANIVANNAN2, A. Choudhary1, P. Ganesan1, S. Sahadevan2, B. Dubashi3

Author affiliations

  • 1 Medical Oncology, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, 605006 - Puducherry/IN
  • 2 Pathology, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, 605006 - Puducherry/IN
  • 3 Medical Oncology Dept., JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, 605006 - Puducherry/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 218P

Background

Acute Lymphoblastic Leukemia (ALL) is a disease of rapid cell proliferation. Onset and development of ALL has also been linked to a reduction in the rate of apoptosis. We aimed to study the rate of in vivo spontaneous apoptosis at baseline in predicting induction outcome for newly diagnosed ALL.

Methods

Newly diagnosed ALL, age 1-39 years, were prospectively enrolled during the study period (December 2020- December 2021) and clinical course was followed till end of induction. Whole blood samples were obtained and assessment of Apoptotic Index (AI) was done using two-parameter Flowcytometry by Annexin- Propidium Iodide staining. The AI was expressed as ratio of Annexin V-positive blast cells divided by total blast cells in the gate.

Results

Total of 70 patients were enrolled, median age was 12.5 years (range, 1-39). Baseline characteristics and induction outcomes are summarized in the table. In the entire cohort, median AI in the blasts was 11.89 (0-87). Patients with high risk had a significantly low AI (median=11) compared to standard risk (median AI=16.9): p=0.026. Post induction, patients who attained CR had a significantly high AI (median=11.8) compared to patients with refractory disease (median AI=3.21): p=0.031. A cut-off of 12 was taken to define high AI (>12) and low AI (<12) for analysing post induction outcomes. In patients with high AI(N=28) and low AI(N=35), CR was 100%(n=28/28) and 85%(n=30/35), while refractory disease was 0% vs 14.3%(n=5/35) respectively. Thus, high AI at baseline was significantly associated with attainment of CR(p=0.037). No association of AI was found with baseline characteristics, D8 response and MRD. Table: 218P

Baseline characteristics and Induction outcomes

Characteristics (N=70) N(%)
Age
1-18 years 49 (70)
19-39 years 21 (30)
Gender
Male 47 (67.1)
Female 23 (32.9)
Subtype
B-ALL 57 (81.4)
T-ALL 13 (18.6)
NCI Risk group
HR 48 (68.6)
SR 22 (31.4)
Protocol
BFM-95 26 (37)
ICiCLe 44 (63)
D8 steroid response
Good response 55 (78.6)
Poor response 13 (18.6)
Unknown (early death)
BM Remission statusCR 58 (82.9)2 (2.9)
Refractory 5 (7.1)
Unknown/death 7 (10)
MRD Positive 9 (12.9)
Negative 53 (75.7)
Unknown 2 (2.9)

Conclusions

Low baseline AI in blast is associated with poor remission rates post induction. Validation of the prognostic role of AI in larger/alternate patient population and for survival outcomes can guide inclusion of apoptosis directed therapy for these high risk subsets.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

JIPMER.

Funding

Indian Council of Medical Research.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.